Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.41 |
| ▸ | DRD1 | P21728 | 11/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15047809 | 0.92 | DRD2 (0.40) | DRD2DRD1MEN1ABCB11LMNA | |
| SCHEMBL24199399 | 0.92 | DRD2 (0.41) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL24199398 | 0.91 | DRD2 (0.40) | DRD2DRD1MEN1ABCB11LMNA | |
| SCHEMBL23125445 | 0.91 | DRD2 (0.44) | DRD2DRD1MEN1ABCB11LMNA | |
| SCHEMBL20751555 | 0.90 | DRD2 (0.40) | DRD2DRD1MEN1ABCB11LMNA | |
| SCHEMBL20751621 | 0.88 | DRD2 (0.38) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL23125441 | 0.85 | DRD1 (0.40) | DRD2DRD1MEN1ABCB11LMNA | |
| SCHEMBL15047808 | 0.81 | DRD2 (0.39) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL20751562 | 0.80 | DRD2 (0.38) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL20751674 | 0.79 | DRD1 (0.38) | DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954250-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954250-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | DRD2 548/4885DRD1 1492/4885MEN1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.